Skip to content

The Effect of Unripe Carob Fruit in Celiac Patients

The Effect of Unripe Carob Fruit on Oxidative Markers and Intestinal Permeability and Microbiota in Celiac Patients

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06300164
Enrollment
30
Registered
2024-03-08
Start date
2024-04-01
Completion date
2024-07-01
Last updated
2024-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Celiac Disease

Keywords

Celiac, Unripe carob, Antioxidant, Microbiota

Brief summary

The aim of this study was to investigate the effects of the consumption of cookies produced by adding the unripe part of carob fruit, which has high insoluble fiber, polyphenol and antioxidant content, on the oxidative parameters (TAS and MDA), intestinal permeability (zonulin, GIP) and microbiota of celiac patients and to develop new products containing unripe carob fruit for celiac patients in this direction.

Detailed description

Between 01.02.2022 and 30.05.2022 by Specialist Dr. Orhan SEZGİN The study will be conducted with 30 volunteers who present to the Mersin University Faculty of Medicine Hospital Gastroenterology Department in Mersin.

Interventions

DIETARY_SUPPLEMENTUnripre Carob

The standard cookies and test cookies (with carob addition) to be used in the study will be produced by Dr. Lecturer Özlem ÖZPAK AKKUŞ at Toros University Nutrition Principles Laboratory. Prof. Dr. Özlem ÖZPAK AKKUŞ will produce the cookies. For standard cookies, 1 egg, 325 g gluten-free flour (Söke flour), 75 grams butter, 50 grams sugar, 10 grams baking powder, 10 grams vanilla will be added and the prepared bread mixture will be divided into 50 equal parts. To make cookies with the addition of unripe carob, the same recipe as the standard cookie will be used to make the test cookie with the addition of unripe carob fruit flour, divided into 50 equal parts, and the amount of unripe carob fruit flour will be added by calculating the daily fiber consumption amount of the patients participating in the study to be 25 g.

Sponsors

Toros University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Masking description

Participants will not know which type of cookies to eat.

Intervention model description

The study will conduct by using a prospective randomized double-blind clinical trial model.

Eligibility

Sex/Gender
ALL
Age
19 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Have been diagnosed with celiac disease within a maximum period of 1 year, * Have not received dietary treatment by a dietitian before * Body Mass Index value between 18.5-25.0 kg/m2, * Who have consumed carob fruit and have not had any allergies, * Signed the Informed Consent Form, * Between the ages of 19 and 64, * Who has not had gastrointestinal tract surgery, * Without mental disorder, * Without inflammatory disease, * No antibiotics or probiotics for the last 1 month, * Not taking prescription drugs and/or fiber supplements, * Not taking vitamin, mineral supplements, * Not during pregnancy and lactation, * Without excessive alcohol consumption (\>2 drinks/day)

Exclusion criteria

* Diagnosed with celiac disease for more than 1 year, * Have gastrointestinal diseases other than celiac disease, * Have previously received dietary treatment by a dietitian, following a diet other than a gluten-free diet, * Body Mass Index values below 18.5 kg/m2 and above 25.0 kg/m2, * Who have consumed carob fruit and have had any allergies, * Not signing the Informed Volunteer Consent Form, * Not between the ages of 19-64, * Gastrointestinal tract surgery, * With a mental disorder, * With inflammatory disease, * Taking antibiotics or probiotics for the last 1 month, * Taking prescription medication and/or fiber supplements, * Taking vitamin and mineral supplements, * During pregnancy and lactation, * Excessive alcohol consumption (\>2 drinks/day)

Design outcomes

Primary

MeasureTime frameDescription
Examination of between group differences regarding serum Total Antioxidant Capacity (TAC)First day at the beginning of the studyExamination of intergroup differences of the concentration of the serum total antioxidant capacity for the determination of antioxidant capacity status in celiac diseases
Examination of between group differences regarding serum Malondialdehyde (MDA)First day at the beginning of the studyExamination of intergroup differences of the concentration of the serum malondialdehyde for the determination of oxidant capacity status in celiac diseases
Examination of between group differences regarding serum zonulinFirst day at the beginning of the studyExamination of intergroup differences of the concentration of the serum zonulin for the determination of intestinal permeability in celiac diseases

Secondary

MeasureTime frameDescription
Comparison of between group differences regarding serum Total Antioxidant Capacity (TAC)Eight weeks after the start of the studyComparison of between group differences of the concentration of the serum total antioxidant for the determination of antioxidant capacity status in celiac diseases
Comparison of between group differences regarding serum Malondialdehyde (MDA)Eight weeks after the start of the studyComparison of between group differences of the concentration of the serum malondialdehyde for the determination of oxidant capacity status in celiac diseases
Comparison of between group differences regarding serum zonulinEight weeks after the start of the studyComparison of between group differences of the concentration of the serum zonulin for the determination of intestinal permeability in celiac diseases

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026